Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

The introduction of point-of-care (POC) assays into clinical practice in patients with inflammatory disease enables on-demand therapeutic decision making. The aim of this study was to compare the POC test Quantum blue (Bühlmann Laboratories) for infliximab (IFX), adalimumab (ADL), and its anti-drug...

Full description

Bibliographic Details
Main Authors:	Francisco José Toja-Camba, Laura García-Quintanilla, Lorena Rodríguez-Martinez, Julia Tomine, Francisco Cajade-Pascual, Carolina Feitosa, Irene Zarra-Ferro, Manuel Barreiro-De-Acosta, Jaime González-López, Cristina Mondelo-García, Anxo Fernández-Ferreiro
Format:	Article
Language:	English
Published:	MDPI AG 2023-11-01
Series:	Pharmaceutics
Subjects:	point-of-care infliximab adalimumab anti-drug antibodies ELISA
Online Access:	https://www.mdpi.com/1999-4923/15/11/2615

Similar Items

Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
by: Tatyana Valentinovna Mezenova, et al.
Published: (2012-04-01)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
by: Florian Rissel, et al.
Published: (2023-06-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Safety profile and side effects of infliximab and adalimumab in inflammatory bowel disease at a referral center in northeastern Brazil
by: Joelma Aurélio de Sousa Santos, et al.
Published: (2024-02-01)

Ustekinumab successfully treated a patient with severe psoriasis vulgaris with primary failure to infliximab and secondary failure to adalimumab
by: Chiharu Tateishi,, et al.
Published: (2015-07-01)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
by: Cheng-Chun Ji, et al.
Published: (2017-04-01)

Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis
by: Weishai Liu, et al.
Published: (2023-05-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study
by: Carmen-Monica Preda, et al.

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
by: M Rodgers, et al.
Published: (2011-02-01)

Adalimumab como alternativa terapéutica en el síndrome de Vogt Koyanagi Harada refractario al infliximab: reporte de caso
by: Eugenio Franklin Moya Ayre, et al.
Published: (2016-03-01)

Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
by: Han Wang, et al.
Published: (2022-11-01)

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10<sup>®</sup> to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies
by: Anne Emmanuelle Berger, et al.
Published: (2022-08-01)

Effect of Infliximab and Adalimumab on Experimental Colitis Following Orally Supplemented Iron
by: John Triantafillidis, et al.
Published: (2017-01-01)

Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges
by: Stefania Cheli, et al.
Published: (2023-06-01)

Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database
by: Tuhin Maity, et al.
Published: (2021-11-01)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
by: Zvonimir Petric, et al.
Published: (2022-08-01)

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease
by: J Dretzke, et al.
Published: (2011-02-01)

Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab
by: Ian Gorovoy, et al.
Published: (2009-10-01)

Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
by: Sara Salvador-Martín, et al.
Published: (2023-01-01)

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model
by: Rachel Archer, et al.
Published: (2016-05-01)

SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB
by: Mariella BAU, et al.
Published: (2017-09-01)

MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy
by: Gregor Jezernik, et al.
Published: (2023-02-01)

The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD
by: Kathryn Demase, et al.
Published: (2023-06-01)

Tratamiento biológico en psoriasis: Revisión bibliográfica Biologic therapy of psoriasis: Literature review
by: MS Lorenzetti, et al.
Published: (2012-06-01)

Evaluation of Therapeutic Drug Monitoring in the Clinical Management of Patients with Rheumatic Diseases: Data from a Retrospective Single-Center Cohort Study
by: Pedersen L, et al.
Published: (2020-10-01)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
by: Matt Stevenson, et al.
Published: (2016-04-01)

Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
by: Sara Salvador-Martín, et al.
Published: (2020-05-01)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
by: Sara Salvador-Martín, et al.
Published: (2021-01-01)

Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
by: Paula Zapata-Cobo, et al.
Published: (2023-10-01)

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis
by: Cristina Membrive-Jiménez, et al.
Published: (2023-05-01)

A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
by: Byron P. Vaughn
Published: (2021-10-01)

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE
by: A. S. Kolbin, et al.
Published: (2016-12-01)

Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases
by: Bruno Laganà, et al.
Published: (2019-01-01)

Efectividad y seguridad en nuestro entorno de adalimumab como tratamiento anti-TNF de primera linea en niños con enfermedad de Crohn
by: Víctor Manuel Navas-López, et al.
Published: (2018-02-01)

PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE
by: Byanca Rossetti Moreira dos SANTOS, et al.
Published: (2020-11-01)

A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease
by: Víctor Manuel Navas-López, et al.
Published: (2018-02-01)

Efficacy of adalimumab for Crohn’s disease in real clinical practice
by: O V Knyazev, et al.
Published: (2017-02-01)